GSK has moved to shore up its R&D pipeline with a strategic-level deal with China's Jiangsu Hengrui Pharma that spans a dozen drug candidates and could be worth up to $12.5 billion.

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ...